SCHEMBL20595977

SCHEMBL20595977

COc1ccc(-c2cccn3cc(Cc4nc5nc(F)ccc5[nH]4)nc23)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MARS2 Q96GW9 9/20 0.54
▸ ALDH1A3 P47895 2/20 0.36
▸ NOS1 P29475 2/20 0.34
▸ NOS2 P35228 2/20 0.34
▸ NOS3 P29474 1/20 0.34
▸ CYP2C9 P11712 1/20 0.32
▸ PPARG P37231 1/20 0.32
▸ TLR9 Q9NR96 1/20 0.32
▸ HSP90AA1 P07900 1/20 0.32
▸ HSP90AB1 P08238 1/20 0.32
▸ PSEN1 P49768 1/20 0.32
▸ PSEN2 P49810 1/20 0.32
▸ APH1B Q8WW43 1/20 0.32
▸ NCSTN Q92542 1/20 0.32
▸ APH1A Q96BI3 1/20 0.32
▸ PSENEN Q9NZ42 1/20 0.32
▸ AMY1A P0DUB6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30145251 1.00 MARS2 (0.54) MARS2ALDH1A3NOS1NOS2NOS3
SCHEMBL30145166 0.91 MARS2 (0.52) MARS2ALDH1A3NOS1NOS2NOS3
SCHEMBL20595826 0.91 MARS2 (0.52) MARS2ALDH1A3NOS1NOS2NOS3
SCHEMBL20595950 0.80 MARS2 (0.79) MARS2NOS1NOS2NOS3CYP2C9
SCHEMBL20595745 0.75 MARS2 (0.54) MARS2
SCHEMBL30145234 0.75 MARS2 (0.54) MARS2
SCHEMBL30145295 0.73 ALDH1A3 (0.43) ALDH1A3PPARGHSP90AA1HSP90AB1
SCHEMBL30145217 0.72 ALDH1A3 (0.42) ALDH1A3PPARGHSP90AA1HSP90AB1
SCHEMBL20596138 0.72 MARS2 (0.79) MARS2NOS1NOS2NOS3CYP2C9
SCHEMBL20595858 0.72 MARS2 (0.46) MARS2NOS1NOS2NOS3CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US claimed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US claimed
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MARS2 12/4885ALDH1A3 1695/4885NOS1 2180/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MARS2 5/4885ALDH1A3 1459/4885NOS1 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback